
News|Articles|September 26, 2025
Salt Substitute Use Rare Among Adults With HTN: Daily Dose
Author(s)Sydney Jennings
Fact checked by: Grace Halsey
Your daily dose of the clinical news you may have missed.
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On September 5, 2025, we reported on a study presented at the American Heart Association's Hypertension Scientific Sessions in Baltimore, Maryland, that examined the long-term trends in salt substitute use among US adults.
The study
Investigators analyzed data from 37 080 adults aged ≥18 years who participated in the National Health and Nutrition Examination Survey (NHANES) between 2003 and March 2020. Participants were categorized by hypertension (HTN) status and treatment: controlled HTN with medication, uncontrolled HTN despite medication, untreated HTN, and normotension. An additional subgroup analysis evaluated individuals eligible to use salt substitutes, defined as those with normal kidney function and not taking medications or supplements affecting potassium levels. Salt use was classified as ordinary salt (eg, iodized, sea, kosher), salt substitutes (potassium-enriched or other formulations), or no salt.
The findings
Overall, fewer than 6% of US adults reported using salt substitutes at any point during the study period. Use peaked at 5.4% in 2013–2014 but declined to 2.5% by 2017–2020. Among adults eligible for salt substitute use, prevalence ranged from 2.3% to 5.1%.
In subgroup analyses, usage was highest among participants with treated, controlled HTN (3.6%–10.5%) and those with treated but uncontrolled HTN (3.7%–7.4%). Among individuals with untreated HTN or normal blood pressure, use remained consistently below 5.6%.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
2
Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154
3
Cannabis Extract Provides LBP Relief Superior to Opioids Over 12 Months in Phase 3 Clinical Trial
4
Measles Outbreak Fails to Push MMR Rates to Herd Immunity Levels, Study Reveals
5